VariZig
Total Payments
$62,067
Transactions
3
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $62,067 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $62,067 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of Antibody-Dependent Cellular Cytotoxicity (ADCC) Antibodies in VARIZIG | Saol International Limited | $48,359 | 0 |
| Evaluation of Antibody-Dependent Cellular Cytotoxicity (ADCC) Antibodies in VARIZIG | Saol Therapeutics Inc. | $8,208 | 0 |
| Assessing Pediatric Provider Practices of Varicella Post-Exposure Prophylaxis | Saol Therapeutics Inc. | $5,500 | 0 |
Top Doctors Receiving Payments for VariZig
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Denver, CO | $62,067 | 3 |
Ad
Manufacturing Companies
- Saol International Limited $48,359
- Saol Therapeutics Inc. $13,708
Product Information
- Type Drug
- Total Payments $62,067
- Total Doctors 0
- Transactions 3
About VariZig
VariZig is a drug associated with $62,067 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Saol International Limited.
Payment data is available from 2019 to 2019. In 2019, $62,067 was paid across 3 transactions to 0 doctors.
The most common payment nature for VariZig is "Unspecified" ($62,067, 100.0% of total).
VariZig is associated with 3 research studies, including "Evaluation of Antibody-Dependent Cellular Cytotoxicity (ADCC) Antibodies in VARIZIG" ($48,359).